Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

f clinical trials, and the potential therapeutic and commercial potential, of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that agreement has ... Administration (FDA) on the design of a pivotal, ... (synthetic hypericin) for the treatment of cutaneous T-cell ...
(Date:9/16/2014)... September 2014 Hologic, Inc. ... heute die Markteinführung des Tomcat, einem ... Europa bekannt gegeben. Der Tomcat ist ... Vereinfachung der präanalytischen Probenverarbeitung. Dies wird ... Arbeitsschritte bei der manuellen Aliquotierung von ...
(Date:9/16/2014)... MEMPHIS, Tenn. , Sept. 16, 2014 ... Hospital investigators has found the chemotherapy dose threshold ... have normal sperm production. The study appears in September ... By clarifying which patients are at highest ... the findings to eventually increase use of pre-treatment fertility ...
Breaking Medicine Technology:Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 3Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
... , INDIANAPOLIS, Dec. 7 Roche Diagnostics ... center in Pleasanton, California, as part of an initiative to ... and independent laboratories on the west and east coasts. Roche ... and is planning to open an additional facility in New ...
... , SILVER SPRING, Md., Dec. 7 ... of excess radiation during CT perfusion imaging of the ... imaging facilities and practitioners with interim recommendations to help ... issued an initial safety notification in October after learning ...
Cached Medicine Technology:Roche Diagnostics Opens State-of-the-Art Training Center in California 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3
(Date:9/17/2014)... 2014 For electronic publishing expert eBooks2go, ... down to a miraculous connection and precision timing. This ... while, but over the past three decades, Ms. Wixom ... was finding it rather tedious to expand her readership ... A phone call, an anniversary, and a second-place trophy ...
(Date:9/17/2014)... Wa (PRWEB) September 17, 2014 Diabetes ... by the Telegraph in August 2014, scientists made ... for diabetes, but still failed. The article indicates that ... Despite this existing fact, there are many forward-thinking entrepreneurs ... diabetes treatment in a natural way. Dr. Kenneth Pullman ...
(Date:9/17/2014)... ICS Learning Group, Inc. won a coveted ... for the Best Use of Games and Simulations for ... operational safety training module that ICS developed for one ... an approach that combined realistic 3D simulation with gamification, ... to a video game, including competition among trainees, to ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Health.Verticalize, a ... people explore their health insurance options in the 2014 ... Network. , Moving forward Health Network ... website. The company has intentionally remained out of the ... network from a single website to its present position ...
(Date:9/16/2014)... Recently, BamboofloorChina.com, the popular online supplier ... of strand woven bamboo floors to its ... big promotion for the new items; the current discount ... is a great shopping season. Therefore, BamboofloorChina.com spares no ... new customers. All practical items offered by BamboofloorChina.com are ...
Breaking Medicine News(10 mins):Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 2Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 3Health News:Versatile Author Wixom Forges Lasting Relationship with Digital Virtuoso eBooks2go 4Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2
... , EMERYVILLE, Calif., Sept. 21 Bionovo, Inc. (Nasdaq: ... the company received a letter from NASDAQ stating that, for the ... stock has closed below the minimum $1.00 per share requirement for ... that the company has been provided a period of 180 calendar ...
... , , , ... Medical, Inc. has made a $15 million equity investment in the company. ... officer of Micell, said, "We are excited to have a company of ... forward to collaborating with them to expand the use of our coating ...
... , , BELMONT, Calif., ... focused on improving the lives of patients with sleep-disordered breathing, ... the Runners-Up Award in The Wall Street Journal ... were published in the September 14, 2009 edition of ...
... results seen with both open surgery and minimally invasive ... -- Successful repair of nasal fractures is possible using ... long as the procedure is appropriate for the type ... be selected by taking into account factors such as ...
... American Gastroenterological Association (AGA) Foundation for Digestive Health and ... businessman and photographer, Bernard Lee Schwartz, has honored his ... for pancreatic cancer research. The $225,000 gift from the ... with funding and protected time for three years to ...
... A multicenter study in Asia found drug-eluting stents ... patients with chronic total occlusions (CTOs) undergoing PCI. Results ... annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by ... the study, "Drug-Eluting Stents for the Treatment of Chronic ...
Cached Medicine News:Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 2Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 3Health News:Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards 2Health News:Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards 3Health News:Best Option for Fractured Nose Varies by Patient 2Health News:California family honors father with second AGA Foundation Research Scholar Award 2Health News:Drug-eluting stents safe, effective for treatment of chronic total occlusions 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: